Navigation Links
GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
Date:8/20/2007

- Dr. Liew awarded Malaysia's Darjah Yang Mulia Pangkuan Negeri -

TORONTO, Aug. 20 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing simple blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that its co-founder and Chief Scientific Officer, Dr. CC Liew, was awarded the Darjah Yang Mulia Pangkuan Negeri (DMPN), a State Honour given by the Governor of Penang in Malaysia. Conferred on prominent people who have served the nation or who excel in their professions, this honour carries with it the title of "Datuk", which is similar to a knighthood in Britain. This award is limited to 150 living persons at any given time.

"We are very proud that this honour has been bestowed on Dr. Liew for demonstrating excellence in the field of disease-specific genomics," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Through Dr. Liew, GeneNews has formed a strong relationship with the Malaysian scientific community. With Malaysia having made a commitment to becoming a major player in the biotechnology sector in South East Asia, Dr. Liew's growing reputation will only further enhance our ability to collaborate with researchers in this region."

In addition to his role as Chief Scientist Officer of GeneNews, Dr. Liew currently holds the positions of Visiting Professor of Medicine and Founding Director of the Cardiovascular Genome Unit at Brigham and Women's Hospital, Harvard Medical School, and Professor Emeritus at the University of Toronto.

About GeneNews

GeneNews is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited

Copyright©2007 PR Newswire.

Related biology technology :

1. Small Tree Communications awarded $2.85M defense contract
2. Alfalight awarded $1.7M from Army Research Lab
3. Mirus Bio awarded patent on RNA delivery
4. UW Biomedical Engineering awarded $2.9 million research grant
5. Two companies awarded state tech grants
6. Alfalight awarded $4.5 million Army Research contract
7. UW-Madison awarded $20 million grant for protein research
8. Esker awarded patent for DeliveryWare Rules Engine
9. Wisconsin technology companies awarded over $24 million in government funding
10. ConjuGon Awarded $250,000
11. Web-based reporting credited with states top healthcare ranking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):